SCHEMBL17488200

SCHEMBL17488200

Nc1ccc2[nH]c(NCc3ccc(Oc4ccc(OC(F)(F)F)cc4)cc3)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
MPO P05164 1/20 0.40
MTOR P42345 1/20 0.40
FABP4 P15090 1/20 0.40
KCNN3 Q9UGI6 1/20 0.39
SCN9A Q15858 1/20 0.38
NTRK1 P04629 1/20 0.38
LMNA P02545 2/20 0.37
HDAC1 Q13547 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37
HIF1A Q16665 1/20 0.37
HPSE Q9Y251 1/20 0.37
GPR39 O43194 1/20 0.37
TYMS P04818 1/20 0.37
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487327 0.97 RAB9A (0.45) RAB9ASMN1; SMN2TP53MPOMTOR
SCHEMBL17488122 0.91 GRIN1 (0.52) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487317 0.88 CYP2C9 (0.40) RAB9ASMN1; SMN2TP53MPOMTOR
SCHEMBL17488216 0.88 RAB9A (0.45) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487328 0.86 RAB9A (0.54) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487331 0.85 RAB9A (0.45) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487319 0.85 RAB9A (0.42) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17488197 0.85 RAB9A (0.45) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487321 0.83 RAB9A (0.42) RAB9ASMN1; SMN2TP53GRIN1GRIN2B
SCHEMBL17487916 0.82 CHEK2 (0.41) RAB9ASMN1; SMN2TP53GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 RAB9A 3982/4885SMN1; SMN2 3381/4885TP53 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.